GNAS and pancreatic neuroendocrine tumor: For example, literature reports that the sensitivity and specificity of NGS for mutations of guanine nucleotide-binding protein-alpha subunit (GNAS), mitogen-associated protein kinase (MAPK), and KRAS for diagnosing mucinous PCLs is 90% and 100%, respectively, whereas multiple endocrine neoplasia 1 (MEN 1) and loss of heterozygosity (LOH) genes are associated with pancreatic neuroendocrine tumors with a combined sensitivity and specificity of 71% and 100%, respectively [111,112].